Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2040 + nivolumab in ctDNA-defined MRD colorectal cancer
NCT05350501Phase 2Terminated
- Sponsor
- Enterome
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EO2040 in colorectal cancer (CRC), sponsored by Enterome. Primary endpoint: Response to Treatment at 6 Months. Started Mar 2023; status: terminated.
02
Drugs
EO2040
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05350501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350501.